Tranexamic Acid

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway New program announced as HMB-003, a potent peptide plasmin inhibitor with a durable half-life designed as a novel antifibrinolytic to reduce bleeding across multiple settings; initiating first-in-human studies in 2H 2026 and preparing for studies in heavy menstrual bleeding in 2027 Long-term extension (LTE) data for sutacimig demonstrate sustained reduction in annualized treated bleeding rate (ATBR) in Glanzmann thrombasthenia (GT) Sutacimig granted FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations; Phase 3 initiation planned 2H 2026 Total of nine presentations reflect the breadth and momentum of Hemab’s pipeline of assets designed to address critical gaps in the treatment of multiple coagulation disorders CAMBRIDGE, Mass. and COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced nine presentations showcasing progress from multiple pipeline programs at the upcoming International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France, on July 11-15, 2026. “People living with serious coagulation disorders remain profoundly underserved, with few targeted preventive treatment options, leaving them to face the relentless burden of unpredictable, disruptive bleeding, with substantial medical, social, psychological, and quality-of-life impact,” said Benny Sørensen, MD, PhD, CEO of Hemab. “We’re advancing three programs with the potential to change that. We are progressing sutacimig to Phase 3 in GT, strengthening the clinical validation of HMB-002 in VWD, and introducing HMB-003, a novel long-acting peptide-based inhibitor of plasmin, a proven therapeutic target in coagulation medicine, central to bleeding in conditions ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management. Our presentations at ISTH 2026 demonstrate our momentum and progress across our pipeline.” For sutacimig, Phase 2 LTE data show sustained reductions in ATBR in GT and describe successful use in the surgical setting and are complemented by real-world and natural-history analyses that help quantify disease burden. Additionally, preclinical data for sutacimig will be presented supporting expansion into Factor VII deficiency (FVIID) where a Phase 2b study is currently in progress. For HMB-002, new first-in-human data validate the approach of simply increasing VWF and FVIII in VWD with durable subcutaneous dosing, and a multiple dose assessment is underway. For HMB-003, preclinical findings describe a novel fatty acid conjugated peptide antifibrinolytic designed for potent plasmin inhibition with durable half-life and subcutaneous dosing allowing the potential for use in multiple high-unmet-need bleeding conditions including heavy menstrual bleeding. Presentation Highlights and Details – The abstracts are now available through the ISTH conference website Sutacimig Sutacimig showed sustained prophylaxis in GT (meaningful reduction in ATBR and high-intensity treatment events and use in surgical setting) in LTE portion of ongoing Phase 2 trial, with real-world and natural-history data underscoring the unmet need, and preclinical validation supporting expansion into FVIID with a Phase 2 proof-of-concept study underway; data expected late 2026 or early 2027. Presentation Number: OC 57.3 Format : Oral Title : Sutacimig Prophylaxis in Glanzmann Thrombasthenia: Results from a Phase 2 Long-Term Extension Date and Time : July 14, 2026, 10:00 AM - 10:15 AM CEST Presentation Number: OC 12.4 Format : Oral Title : Elucidating Sutacimig’s Dual Mechanism in Factor VII Deficiency: TF-Pathway Enhancement via FVIIa Accumulation as the Significant Driver of Hemostatic Activity Date and Time : July 12, 2026, 10:00 AM - 10:15 AM CEST Presentation Number: PB3513 Format : Poster Title : Persistent Weekly Bleeding Burden Across the Lifespan in Glanzmann Thrombasthenia: Analysis of the GT360 Patient Survey Date and Time: July 14, 2026, 1:45 PM CEST Presentation Number: PB3523 Format : Poster Title : Elevated Depression Prevalence and Psychological Burden Associated with Bleeding Frequency in Glanzmann Thrombasthenia Date and Time : July 14, 2026, 1:45 PM CEST Presentation Number: PB3495 Format : Poster Title : Substantial Bleeding Burden and Limited Prophylaxis Use in Glanzmann Thrombasthenia: Prospective Real-World Data from ATHN Transcends Date and Time : July 14, 2026, 1:45 PM CEST HMB-002 HMB-002’s first-in-human data from an ongoing Phase 1/2 clinical trial support a non-replacement subcutaneous approach that elevates endogenous VWF and FVIII, with sustained hemostatic elevations and no thromboembolic events observed; multiple dose assessment is currently underway to enable a potential new prophylaxis paradigm in VWD. Presentation Number: OC 12.5 Format : Oral Title : First-in-human investigation of HMB-002: a subcutaneous antibody for prophylactic management of Von Willebrand disease Date and Time: July 12, 2026, 10:15 AM - 10:30 AM CEST HMB-003 HMB-003 is a potent subcutaneous plasmin inhibitor with a durable half-life that blocks fibrinolysis independently of the plasminogen activation pathway (tPA or uPA). HMB-003 inhibited fibrinolysis with greater potency than tranexamic acid in a human whole-blood flow model and demonstrated long half-life in preclinical models, supporting infrequent dosing with potential across multiple high-unmet-need conditions; first-in-human studies are planned for the second half of 2026. Presentation Number: OC 05.1 Format : Oral Title : A long-acting peptide plasmin inhibitor with extended antifibrinolytic activity enabling once-per-cycle subcutaneous treatment for heavy menstrual bleeding: Preclinical development of HMB-003 Date and Time : July 11, 2026, 1:00 PM - 1:15 PM CEST Presentation Number: OC 09.5 Format : Oral Title : HMB-003, a long-acting peptide plasmin inhibitor, potently inhibits fibrinolysis and localizes with fibrin in a human whole blood microfluidic flow model Date and Time : July 11, 2026, 2:00 PM - 2:15 PM CEST Presentation Number: PB1414 Format: Poster Title : Optimization of the Halo Fluorescence Fibrinolysis Assay: How Plasma Overlay and Timing Influence Antifibrinolytic Assessment Date and Time: July 12, 2026, 1:45 PM CEST About Glanzmann Thrombasthenia Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international natural history study (Glanzmann's 360) revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week with 65% requiring a bleed-related hospital visit in the prior six months. These bleeding episodes significantly impacted patients' mental health and quality of life, with over 80% having missed work or school, over 50% facing limitations in attending social events, and over 50% experiencing restrictions in travel. To date, there are no approved prophylactic treatment options for GT. About Sutacimig (formerly HMB-001) Sutacimig is a subcutaneously administered bispecific antibody that is designed to bind and stabilize endogenous Factor VIIa with one antibody arm and bind to TLT-1 on activated platelets with the other arm. This mechanism is designed to allow for the accumulation of endogenous Factor VIIa in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it facilitates hemostatic plug formation. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration has granted Fast Track Designation, Orphan Drug Designation, and Breakthrough Therapy Designation to sutacimig for the treatment of GT, and the UK Medicines and Healthcare products Regulatory Agency has awarded sutacimig designation under the Innovative Licensing and Access Pathway (ILAP); it has been designated as an orphan medicinal product in the European Union for the treatment of GT, and the European Medicines Agency (EMA) has granted sutacimig Priority Medicines (PRIME) designation. For more information, please visit clinicaltrials.gov (NCT06211634). About Von Willebrand Disease Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying biology of the disease.‍ About HMB-002 HMB-002 is a monovalent human antibody being developed as the first-in-class subcutaneous prophylactic treatment for Von Willebrand Disease targeting the underlying cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852). About HMB-003 HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with a durable half-life — a proven therapeutic target in coagulation medicine — being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site, HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. HMB-003 is optimized to provide sustained bleed protection across multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management. About Hemab Therapeutics Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an anti-fibrinolytic targeting plasmin inhibition in preclinical development for multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management. Learn more at hemab.com . Follow us on LinkedIn , Facebook , Instagram , and X . Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, the anticipated timelines for reporting data from Hemab’s clinical trials, the anticipated timelines for initiating a Phase 3 clinical trial of sutacimig and first-in-human studies of HMB-003, the clinical potential of sutacimig, HMB-002 and HMB-003, Hemab’s plans to expand its pipeline, and the sufficiency of Hemab’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release. Media: Deerfield Group Peg Rusconi peg.rusconi@deerfieldgroup.com Investors: Hemab Therapeutics Mads Behrndt mads@hemab.com

Represents the Company’s 27th product launch since inception in October 2023 SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. The product contains the same active ingredient as CYKLOKAPRON ® , as approved by the U.S. Food and Drug Administration, and is indicated for use in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. Each vial of Tranexamic Acid in 0.7% Sodium Chloride Injection contains 1,000 mg per 100 mL (10 mg per mL) and is available as a carton of 10 single-dose ready-to-use vials. “We are proud to continue expanding our portfolio with the addition of Tranexamic Acid in a ready-to-use format,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “This presentation enables healthcare providers to deliver safe and efficient care while helping reduce preparation time and potential medication errors, reinforcing our long-standing value proposition as a trusted partner to hospitals and providers.” In line with Avenacy’s mission to champion patient safety and streamline patient care, Tranexamic Acid in 0.7% Sodium Chloride Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Avenacy will begin shipping Tranexamic Acid in 0.7% Sodium Chloride Injection to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards. U.S. sales of Tranexamic Acid Injection were approximately $30.2 million for the twelve months ending in March 2026, with ready-to-use presentations accounting for approximately $15 million of total sales. 1 Indications Tranexamic Acid Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and to reduce the need for replacement therapy during and following tooth extraction. Contraindications Tranexamic Acid Injection is contraindicated: In patients with subarachnoid hemorrhage. In patients with active intravascular clotting. In patients with hypersensitivity to tranexamic acid or any of the ingredients. Please see link for Full Prescribing Information. CYKLOKAPRON ® is a registered trademark of Pfizer. 1 Source: IQVIA About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit . Contacts Media Contact FTI Consulting Avenacy@fticonsulting.com